Updates from Phlow
Move Strengthens America’s Supply Chain and Supports COVID-19 Response.
PR Newswire | May 19, 2020
The U.S. government signed a $354 million four-year contract with new pharmaceutical company Phlow Corp. to increase American production of medications that may help treat Covid-19 in a bid to avoid potential supply chain shortages, with the potential to extend the contract to $812 million for the next ten years.
Forbes | May 19, 2020
A new Richmond-based pharmaceutical manufacturing company has received a $354 million federal contract to help build a strategic, national reserve of essential medications and to make active ingredients for more than a dozen medicines used to treat patients with COVID-19.
Richmond Times Dispatch | May 19, 2020
White House officials called the multi-million dollar contract with Virginia-based Phlow Corp. a potential landmark in returning pharmaceutical manufacture from overseas.
Washington Post | May 19, 2020
Other News
Health security is critical to national security. The Covid-19 pandemic is a moment to re-evaluate U.S. dependence on China for pharmaceutical ingredients and to solidify the pharmaceutical supply chain.
The Wall Street Journal | April 28, 2020
As the federal government took steps to ease shortages of some critical sedatives and other drugs used in the ICU, pharmacy and anesthesiology groups say more needs to be done.
MedPage Today | April 10, 2020
Countries around the world are scrambling to source more ventilators for patients infected with coronavirus, but doctors fear that these will be useless without essential drugs to keep patients comfortable, the Bureau of Investigative Journalism can reveal.
The Bureau of Investigative Journalism | April 9, 2020
The Massachusetts governor struck a deal for supplies but needed a way to transport them. The result was a tense saga and a shipment on the NFL team’s 767.
The Wall Street Journal | April 2, 2020
White Papers
Download Phlow’s White Paper on Addressing Essential Medicine Shortages